EMA's trial design hinders Eisai's Halaven reimbursement in Germany
This article was originally published in Scrip
Eisai's end of life breast cancer drug Halaven (eribulin) offers a "hint" of "unquantifiable" additional benefit against comparators for patients unable to continue treatment with taxanes or anthracyclines, according to a preliminary benefit assessment by the German health technology appraisal body, IQWiG. Furthermore, the drug offers no additional benefit for patients able to continue with taxanes or anthracyclines, said the institute.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.